Pasithea Therapeutics announces preclinical data on PAS-004

Pasithea Therapeutics (KTTA) announced new preclinical data demonstrating that PAS-004 provides superior inhibition of ETS2-driven inflammatory responses compared to selumetinib in a human macrophage model of chronic inflammation that mimics the inflammatory milieu seen in inflammatory bowel disease. Key findings of this study are: – Superior and stronger suppression of ETS2 signaling: At all doses, PAS-004 showed greater downregulation of ETS2-regulated genes than selumetinib. – Suppression of core macrophage functions: PAS-004 significantly reduced ETS2-dependent functions such as cytokine production, phagocytosis, and reactive oxygen species generation, all known to be central to chronic inflammation. – Deeper mechanistic engagement: Gene Set Enrichment Analysis revealed that PAS-004’s effects more closely mirrored ETS2 knockout profiles, with a higher normalized enrichment score and greater statistical significance as compared to selumetinib.